Recap AMCP 2024: Our thought leadership in action
By AmerisourceBergen
From delivering educational sessions on the evolution of the AMCP format for formulary submissions and the role of pre-approval dossiers in a successful product launch to award-winning research, Cencora was a proud supporter of this year's conference.
Explore some of our expert contributions and related content that showcased our commitment to helping our biopharma partners accelerate product success.
Award-winning research
- Changes in US payer biosimilar coverage policies of granulocyte colony stimulating factor products
- Early implementation of PIE for specific drug categories
- Mind the “pre-approval” gap: Payer pre-approval information needs and how manufacturers can better meet them
- Sourcing value: understanding payer perceptions of value assessment information for formulary decision-making
- US payer perceptions on formulary evaluation and management of cell and gene therapies
- Beyond value assessment reports: a review of payer perspectives on ICER’s initiatives and tools
- Impact of route of administration on access and reimbursement of cell and gene therapies: a survey of US payers
FormularyDecisions®
Innovation and Impact Award
In the ever-evolving landscape of healthcare, where decisions shape outcomes and information is paramount, the reliance on digital channels for accessing crucial product-related data has become increasingly critical.
The Innovation and Impact Award serves as a beacon of recognition for those who have demonstrated exceptional support for healthcare decision makers needs in formulary decision making. It is awarded annually to distinguished recipients in two distinct categories: mid-to-large biopharma and emerging biopharma.
Congratulations to SpringWorks Therapeutics (Emerging biopharma category) and AbbVie Inc (Mid-to-large biopharma category).
The Innovation and Impact Award serves as a beacon of recognition for those who have demonstrated exceptional support for healthcare decision makers needs in formulary decision making. It is awarded annually to distinguished recipients in two distinct categories: mid-to-large biopharma and emerging biopharma.
Congratulations to SpringWorks Therapeutics (Emerging biopharma category) and AbbVie Inc (Mid-to-large biopharma category).
Watch the interview
We were thrilled to recognize SpringWorks Therapeutics with the Emerging biopharma company Innovation and Impact Award at AMCP Annual 2024.
Learn more about SpringWorks Therapeutics’ approach to digital engagement with healthcare decision makers, and how FormularyDecisions fits into their digital strategy, in this interview with Zack McCormack, Director, Value and Access.
.jpg?h=320&iar=0&w=540&useCustomFunctions=1¢erCrop=1&hash=DDA1D7BEE906940394C769FA6454A08B)